Drug intelligence / Profile preview

PS-35

Development stage: Unknown
Lead developer: Agastiya Biotech
Modality: Small Molecules
Administration: Topical

Overview

PS-35 is a topical botanical small molecule developed by Agastiya Biotech for the treatment of chronic plaque psoriasis. The drug represents a fusion of traditional Eastern botanical insights and Western pharmaceutical development methodologies. Following clinical trials conducted in India in 2018, PS-35 was licensed to Lupin Pharmaceuticals for further development and commercialization. Although the specific molecular target and mechanism of action have not been publicly disclosed, the drug is characterized as a botanical-derived small molecule intended for topical application to manage psoriatic lesions.

Beyond the preview

Go deeper on PS-35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PS-35.

Explore the full profile